BioBoss – Details, episodes & analysis

Steve Uden, co-founder and CEO of RallyBio, shares his insights about leadership in biopharma and how Rallybio is working to to profoundly  change the odds for patients living with rare diseases.

Karine Rossignol, co-founder and CEO of Smart Immune, shares her insights with BioBoss host John Simboli about leadership in biopharma and how Smart Immune is working to harness a patient's own thymus to re-arm the immune system against cancer and infection.

Lisa Deschamps, CEO of AviadoBio, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how AviadoBio is working to develop transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders.

Leonard Mazur, founder and CEO of Citius Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Citius is working to unlock the potential of first-in-class critical care therapeutics, with a pipeline of anti-infectives in oncology, adjunct cancer care and stem cell therapy.

Dario Neri, co-founder and CEO of Philogen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Philogen is working to discover and develop targeted therapies to treat cancer and chronic inflammation.

Naseem Amin,  CEO of Orphalan, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Orphalan is working to transform rare disease treatment.

Hartmut Ehrlich,  CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

Ivo Timmermans, co-founder and  CEO of Pleco Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Pleco is working to develop breakthrough therapies that change the balance in the treatment of cancer.

Philipp Spycher, co-founder and  CEO of Araris Biotech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Araris is working to develop a linker technology for antibody-drug conjugates that enables attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Pat Arensdorf, founder and  CEO of Exai Bio, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Exai is working to develop a next-generation RNA-based platform to deliver actionable insight into cancer biology from a simple blood draw.